Prostate Cancer

Despite presenting with high-risk disease, Black patients with prostate cancer who enrolled on radiation therapy clinical trials were reported to have better rates of biochemical recurrence, distant metastases, and prostate cancer–specific mortality than White patients.

A meta-analysis of 2 phase 3 randomized trials found that combination therapy including androgen deprivation therapy led to higher rates of metastasis-free survival for patients with high-risk non-metastatic prostate cancer.

Aaron Berger, MD, discussed updates in the treatment of nonmetastatic castration-resistant prostate cancer.

A. Oliver Sartor, MD, discussen treatment options for PARP inhibitor use in patients with prostate cancer.

The decision by the FDA to approve prostate cancer imaging product TLX591-CDx, a kit to aid in the preparation of gallium-68 gozetotide injections, should make 68Ga-based PSMA-PET more broadly accessible.

CancerNetwork® takes a deep dive into ongoing clinical research that holds promise in the prostate cancer space as the year 2021 comes to a close.

Aaron Berger, MD, shares unmet needs and challenges in managing patients with nmCRPC.

Dr Aaron Berger comments on quality of life data and the role of patient preference in nmCRPC.

A prostate cancer expert discusses comorbidities and dose alterations with next-generation androgen receptor inhibitors in nmCRPC.

Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.

Daniel P. Petrylak, MD, leads the discussion on sequencing treatment for a patient with mCRPC, such as in case 2, who progresses on docetaxel therapy.

The phase 3 ARASENS trial, which assessed the use of darolutamide and docetaxel in patients with metastatic hormone-sensitive prostate cancer, met its primary end point of significantly improved overall survival.

The National Comprehensive Cancer Network has reversed its previous ruling in September and instead recommends patients with low-risk prostate cancer receive active surveillance.

Alicia Morgans, MD, MPH, lists several advances being made while treating metastatic prostate cancer and offers advice to clinicians who don’t see patients with the disease very often.

An expert examines sequencing strategies for the treatment of metastatic prostate cancer.

Dr Aaron Berger shares updated safety data on next-generation androgen receptor inhibitors and impact of safety profile on treatment selection in nmCRPC.

Aaron Berger, MD, discusses adverse events with enzalutamide, apalutamide and darolutamide and their management.

Prostate cancer experts review the use of PSMA PET/CT imaging and Axumin imaging for patients with metastatic castration-resistant prostate cancer.

Raoul S. Concepcion, MD, presents the case of a 64-year-old-man with mCRPC, and Jason M. Hafron, MD, CMO, leads the discussion on the optimal treatment approach for the given case.

Men with localized prostate cancer were most likely to select treatment with radiotherapy over surgery and its associated adverse effects.

Daniel P. Petrylak, MD, leads the discussion on approaching treatment of high-volume metastatic castration-naïve prostate cancer.

A panel of experts in prostate cancer examine the use of conventional imaging and PSMA PET/CT and the impact on their approach to the management of mCNPC.

A prostate cancer expert reviews trial design and efficacy data with next-generation androgen receptor inhibitors.

Dr Aaron Berger discusses systemic therapy options, treatment selection and monitoring for patients with nonmetastatic castrate-resistant prostate cancer (nmCRPC).

Dr Morgans discusses how patient access impacts treating metastatic prostate cancer.

Alicia Morgans, MD, MPH, mentions other factors clinicians need to consider before adding PARP inhibitors to metastatic prostate cancer therapy.

Dr Raoul S. Concepcion presents the case of a 69-year-old man with metastatic castration-naïve prostate cancer (mCNPC), and the panel shares their personal approaches to treatment.

Raoul S. Concepcion, MD, FACS, poses polling questions for the audience’s medical specialty and the percent of patients they receive with prostate cancer.

The aim of this meta-analysis is to analyze the efficacy of these drugs in the treatment of mCRPC in terms of progression-free survival (PFS) and overall survival (OS), using the results of completed trials.

Brian T. Helfand, MD, PhD, and Steven E. Finkelstein, MD, discuss the potential of 18F-fluciclovine PET/CT to guide prostate cancer decision-making.